A live symposium education at European Society For Medical Oncology Congress (ESMO 2026) on 23 – 27 October 2026 to address the clear need to improve the knowledge and competence of HCPs in relation to mCRPC. The symposium will utilize an innovative, highly interactive format in which the faculty (of 2 clinical experts and a patient advocate) and audience explore emerging evidence and contemporary best practices through the lens of patient-centred care. By uniting a patient advocate with a panel of clinical experts, the session will amplify patient voices and impart the ongoing experiences and unmet needs among the real-world population; following this, the clinical faculty will summarise recent data evaluating novel treatment approaches in the 1L management of mCRPC, describing how best practice approaches are evolving based on this evidence. This will provide learners with baseline knowledge to prepare them to engage optimally with the subsequent panel discussion formats, in which the full faculty (including both the patient advocate and clinical experts) will discuss how to individualise treatment approaches upon first progression to mCRPC, as well as further considerations to optimise patient support beyond treatment selection (such as the importance of bone health agents among this population). The ultimate goal of our program is to improve provision of shared decision-making and optimized treatment plans in mCRPC by improving clinician knowledge and competence surrounding treatment selection and sequencing, and empowering them to educate and communicate with patients on these topics.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Pricing
$54 – $4,128 per course
typical $950 · based on 60 courses listed here
Collected from the provider’s public pages · source
Specialties served/covered
- Cardiovascular Disease
- Communication & Shared Decision-Making
- Critical Care Medicine
- Dermatology
- Diagnostic Radiology
- Emergency Medicine
- Endocrinology, Diabetes & Metabolism
- Evidence-Based Medicine & Research
- Foot & Ankle Surgery
- Gastroenterology
- General Internal Medicine
- General Pediatrics
- Head & Neck Surgery
- Interventional Radiology
- Medical Oncology
- Nephrology
- Neurology
- Neuromuscular Medicine
- Nuclear Medicine
- Obstetrics & Gynecology
- Pediatric Radiology
- Physical Medicine & Rehabilitation
- Pulmonary Disease
- Radiation Oncology
- Rheumatology
- Urological Oncology
- Vascular Neurology
- Vascular Surgery
- Cardio-Vascular
- Cross-Specialty
- Emergency & Critical Care
- ENT & Head Neck
- GI & Liver
- Internal Medicine
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Orthopedics
- Pediatrics
- Radiology
- Rehabilitation
- Urology
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Conference / congress
- Credit · Up to 1.5 credits
- Commercial Support
-
WhenOct 23, 2026
-
Medscape, LLC Improving mCRPC Outcomes Using Radiopharmaceuticals: Evidence to Implementation
-
PRIME Education, Inc. (PRIME®) From Trial to Treatment: Integrating Targeted Radionuclide Therapy Data Into Evidence-Based mCRPC Care
-
University of Chicago School of Medicine Systems-Based Solutions for Addressing Treatment Delays in Black Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
-
PeerVoice, Siyemi Europe Limited PeerVoice – Navigating the Changing Landscape of mCRPC Management: Reviewing Roads Travelled and Exploring Emerging Directions – Enduring
-
PeerVoice, Siyemi Europe Limited PeerVoice – Re-Evaluating the Role of Radiopharmaceuticals in the Management of mCRPC: How Should Recent Data Inform Individualized Treatment? – Enduring
-
PeerVoice, Siyemi Europe Limited PeerVoice – Translating Evidence Into Individualized Decisions Across the Spectrum of SCLC: Expert Insights on Contemporary Cases
